Hypergonadotropic hypogonadic amenorrhea (World Health Organization III) and osteoporosis.
OBJECTIVE
To assess the bone mineral density in World Health Organization (WHO) III women after hormone replacement therapy.


METHODS
We studied the bone mineral density of 41 women with premature ovarian failure (hypergonadotropic hypogonadic amenorrhea--WHO III) before and during hormone replacement therapy.


METHODS
All WHO III women were recruited from the Outpatient Department of the First Department of Gynecology and Obstetrics, University of Vienna Medical School, Austria, a public University Hospital.


METHODS
Forty-one patients, 30 healthy women.


METHODS
Twenty-eight of 41 WHO III women received cyclic hormone replacement therapy consisting of 0.625 mg conjugated estrogen (days 1 to 30) and 5 mg medrogeston (days 20 to 30) in addition, with a 7-day interval.


METHODS
The bone mineral density was evaluated by single photon absorptiometry and dual energy x ray absorptiometry every 6 months (single photon absorptiometry six times, dual energy x ray absorptiometry four times).


RESULTS
The bone mineral density in young women with hypergonadotropic hypogonadic amenorrhea (WHO III) was lower than in age-matched controls. Hormone replacement therapy produced an increase in bone mineral density in 28 WHO III women, whereas bone mineral density remained quite constant in the women without therapy.


CONCLUSIONS
Hormone replacement therapy increases the bone mineral density of women with hypergonadotropic hypogonadic amenorrhea. Hormones should be substituted early and consistently in affected patients.
Metka
M
M
First Department of Gynecology and Obstetrics, University of Vienna Medical School, Austria.
Holzer
G
G
Heytmanek
G
G
Huber
J
J
D000328:Adult; D000568:Amenorrhea / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D015519:Bone Density; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010024:Osteoporosis / Q000150:complications*; D016649:Primary Ovarian Insufficiency / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D012016:Reference Values
D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone